🇺🇸 FDA
Patent

US 8304385

Macrocyclic tetrazolyl hepatitis C serine protease inhibitors

granted A61KA61K38/212A61K38/215

Quick answer

US patent 8304385 (Macrocyclic tetrazolyl hepatitis C serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Nov 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K38/212, A61K38/215, A61P, A61P1/16